Soligenix Reports Q3 2026 Financial Results and Pursues Strategic Options

Soligenix, Inc. reported a Q3 2026 net loss of $1.1 million, an improvement from the prior year. The biopharmaceutical company is actively exploring strategic options to enhance stockholder value, including advancing its SGX945 for Behçet's disease and its ThermoVax® vaccine platform. With $9.0 million in cash, Soligenix anticipates funding operations into Q2 2028, providing a runway for its strategic initiatives.